Who is on it, and how far along Every drug ChEMBL records acting on ROS1, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Approved3 Crizotinib Crizotinib SponsorPfizer ModalitySmall molecule ActionInhibitor Open trials39 Entrectinib Entrectinib SponsorRoche ModalitySmall molecule ActionInhibitor Open trials26 Repotrectinib Repotrectinib SponsorBristol-Myers Squibb ModalitySmall molecule ActionInhibitor Open trials8 Phase 21 Taletrectinib Taletrectinib SponsorNuvation Bio ModalitySmall molecule ActionInhibitor Open trials6
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Proto-oncogene tyrosine-protein kinase ROS inhibitor. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 28 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma Entrectinib Phase 2 Not yet recruiting St. Jude Children's Research Hospital Nov 4, 2026 Master Protocol for Basket Clinical Trials of Targeted Therapies Based on Proteome and Whole Exome Sequencing Screening in Patients With Advanced Solid Tumors Crizotinib Not applicable Active, not recruiting National Cancer Center, Korea Oct 23, 2026 Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations Entrectinib Phase 2 Not yet recruiting Shanghai Zhongshan Hospital Sep 21, 2026 A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer Crizotinib Phase 3 Not yet recruiting Guangzhou JOYO Pharma Co., Ltd Sep 11, 2026 Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma Crizotinib Phase 3 Recruiting IDEAYA Biosciences Sep 4, 2026 Molecularly Tailored Therapy in Advanced Pancreatic Cancer Crizotinib Phase 2 Not yet recruiting Herlev Hospital Sep 3, 2026 Repotrectinib Post-Marketing Surveillance in Pediatric Patients With NTRK Fusion-Positive Tumors in Japan Repotrectinib — Recruiting Bristol-Myers Squibb Aug 10, 2026 Study on the Effect of Famotidine on Pharmacokinetics of Taletrectinib Taletrectinib Phase 1 Not yet recruiting Nuvation Bio Inc. Aug 3, 2026 Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion Repotrectinib — Not yet recruiting Bristol-Myers Squibb May 20, 2026 Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa) Crizotinib Phase 1 / Phase 2 Not yet recruiting China Medical University Hospital May 1, 2026 A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver Function Crizotinib Phase 1 Not yet recruiting Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Apr 20, 2026 Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell Carcinoma Crizotinib — Recruiting First People's Hospital of Hangzhou Oct 3, 2025 Study on the Mechanism of Acquired Resistance of Entrectinib Entrectinib — Recruiting Fudan University Sep 30, 2025 Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression Entrectinib, Taletrectinib — Not yet recruiting Innovent Biologics (Suzhou) Co. Ltd. Sep 30, 2025 Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) Taletrectinib Phase 3 Recruiting Nuvation Bio Inc. Sep 4, 2025 Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases Taletrectinib — Recruiting Innovent Biologics (Suzhou) Co. Ltd. Jun 6, 2025 Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC Crizotinib, Entrectinib — Not yet recruiting National Cancer Center, China Nov 19, 2024 Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS Entrectinib Phase 2 Not yet recruiting Peking University Shenzhen Hospital Nov 18, 2024 A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Taletrectinib Phase 3 Recruiting Nuvation Bio Inc. Aug 21, 2024 Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC Repotrectinib Phase 2 Recruiting Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer Aug 13, 2024 Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors Entrectinib Phase 2 Recruiting St. Jude Children's Research Hospital Jul 30, 2024 Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer Entrectinib Phase 2 Recruiting West China Hospital Jul 1, 2024 Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis Repotrectinib Phase 2 Recruiting MedSIR Mar 18, 2024 A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) Repotrectinib Phase 3 Active, not recruiting Bristol-Myers Squibb Nov 20, 2023 A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer Repotrectinib Phase 1 / Phase 2 Recruiting Memorial Sloan Kettering Cancer Center Aug 13, 2021 Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC Taletrectinib Phase 2 Active, not recruiting Nuvation Bio Inc. Jun 9, 2021 A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations Repotrectinib Phase 1 / Phase 2 Recruiting Turning Point Therapeutics, Inc. Sep 19, 2019 A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements Repotrectinib Phase 1 / Phase 2 Recruiting Turning Point Therapeutics, Inc. Mar 28, 2017
Show all 28Diseases most associated with it Open Targets association score, 0 to 1; all associations Non-small cell lung carcinoma 0.71 Non-small cell lung carcinoma Value0.71 Neoplasm 0.61 Neoplasm Value0.61 Lung adenocarcinoma 0.59 Lung adenocarcinoma Value0.59 Cancer 0.54 Cancer Value0.54 Lung carcinoma 0.43 Lung carcinoma Value0.43 Melanoma 0.40 Melanoma Value0.40 Open Squamous cell lung carcinoma 0.39 Squamous cell lung carcinoma Value0.39 Cutaneous melanoma 0.38 Cutaneous melanoma Value0.38 Open Spitz nevus 0.37 Spitz nevus Value0.37 Melanocytic neoplasm 0.37 Melanocytic neoplasm Value0.37 Lymphoid neoplasm 0.37 Lymphoid neoplasm Value0.37 Meningothelial Meningioma 0.37 Meningothelial Meningioma Value0.37 Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5568 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-19. Gene name, function (UniProt P08922 , CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets